Expert Interview
A Second Opinion: Discussing the potential of Ojjaara (momelotinib), a JAK inhibitor recently approved by the FDA for the treatment of myelofibrosis and anemia.
Ticker(s): GSKInstitution: Mount Sinai
- Assistant Professor at the Mount Sinai Health System (Icahn School of Medicine).
- Treats ~15 patients with Systemic Mastocytosis and very familiar with the data on avapritinib.
- Research interests include myeloproliferative neoplasms, especially polycythemia vera and myelofibrosis, as well as acute myeloid leukemia, hemophagocytic lymphohistiocytosis, systemic mastocytosis, and chronic myelomonocytic leukemia and has published extensively on these topics.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
